This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Feb 7;373(9662):457-8; author reply 459.

doi: 10.1016/S0140-6736(09)60161-6.

Telmisartan in high-risk patients intolerant of ACE inhibitors

Matthew Thompson, Carl Heneghan, Rafael Perera

PMID: 19200908
DOI: 10.1016/S0140-6736(09)60161-6

Comment

Telmisartan in high-risk patients intolerant of ACE inhibitors

Matthew Thompson et al. Lancet. 2009.

. 2009 Feb 7;373(9662):457-8; author reply 459.

doi: 10.1016/S0140-6736(09)60161-6.

Authors

Matthew Thompson, Carl Heneghan, Rafael Perera

PMID: 19200908
DOI: 10.1016/S0140-6736(09)60161-6

No abstract available

PubMed Disclaimer

Comment on

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal